A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Conjupro Biotherapeutics, Inc.
Epsilogen Ltd
Conjupro Biotherapeutics, Inc.
GlaxoSmithKline
Rondo Therapeutics
Dragonfly Therapeutics
Atavistik Bio, Inc
Merck Sharp & Dohme LLC
WestVac Biopharma Co., Ltd.
Alterome Therapeutics, Inc.
Daewoong Pharmaceutical Co. LTD.
ViroMissile, Inc.
Pfizer
Tizona Therapeutics, Inc
SEED Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Pheon Therapeutics
Novartis
OncoNano Medicine, Inc.
Sairopa B.V.
Degron Therapeutics Co.
Pfizer
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Masonic Cancer Center, University of Minnesota
Nuvectis Pharma, Inc.
Context Therapeutics Inc.
Thomas Jefferson University
Revolution Medicines, Inc.
Inspirna, Inc.
Ohio State University Comprehensive Cancer Center
Immatics US, Inc.
Checkpoint Therapeutics, Inc.
Zymeworks BC Inc.
Compugen Ltd
AstraZeneca
Carisma Therapeutics Inc
Jazz Pharmaceuticals
Eli Lilly and Company
Vincerx Pharma, Inc.
Vincerx Pharma, Inc.
Astellas Pharma Inc
Astellas Pharma Inc
Advaxis, Inc.
Exelixis
Kyowa Kirin Co., Ltd.